Abstract
Aims: To investigate the feasibility of hyperthermic isolated regional perfusion (HIRP) with carboplatin in the management of locally recurrent and/or intransit metastases of melanoma or locally advanced soft tissue sarcoma.
Methods: Three patients, two with locally advanced melanoma and one with a low-grade liposarcoma of the lower extremity, were treated with HIRP under mild hyperthermia (39-40 degreesC) with 125mg carboplatin/l perfused limb volume.
Results: No systemic toxicity was observed. Local toxicity consisted of post-perfusion oedema present in all three patients which resolved within 2 weeks. Clinically, a persistent local neuropathy was observed in all three patients, two of which were confirmed by electromyogram and nerve conduction study. Severe motor-sensory neuropathy was located mainly in the peroneal and sural nerves of the perfused limbs. Pharmacokinetic parameters of the carboplatin showed a higher concentration of carboplatin in the skin compared to the muscle. The two melanoma patients showed a complete response but developed local recurrences within 1.5 years after perfusion. The third patient underwent a delayed excision of the sarcoma 8 weeks after perfusion which revealed 50% viable tumour. One of the melanoma patients and the sarcoma patient died from lung metastases 56 and 31 months pest-perfusion treatment, respectively. The other melanoma patient is alive 95 + months post-perfusion treatment.
Conclusions: The local neurotoxicity observed did not warrant further research of carboplatin in HIRP. (C) 2000 Harcourt Publishers Ltd.
Original language | English |
---|---|
Pages (from-to) | 792-797 |
Number of pages | 6 |
Journal | European Journal of Surgical Oncology |
Volume | 26 |
Issue number | 8 |
Publication status | Published - Dec-2000 |
Keywords
- perfusion
- carboplatin
- melanoma
- sarcoma
- TUMOR-NECROSIS-FACTOR
- SOFT-TISSUE
- FACTOR-ALPHA
- MALIGNANT-MELANOMA
- INTERFERON-GAMMA
- LOWER-EXTREMITY
- PHASE-I
- CISPLATIN
- MELPHALAN
- SARCOMAS